Extramedullary Multiple Myeloma Responds to Dual-Targeting CAR T-Cell Therapy

Chimeric antigen receptor T-cell therapy targeting both BCMA and CD38 induced an objective response in>90% of patients with multiple myeloma who had been treated with at least 3 prior therapies and whose disease had spread outside of the bone marrow.
Source: CancerNetwork - Category: Cancer & Oncology Authors: Source Type: news